[Clinical trial with long-term therapy of generalized plasmacytoma].
The authors report on findings in long-term therapy made by means of a combination of cyclophosphamide as attack dosis (partially also with polychemotherapy--COP, COPP-scheme) and double plasmapheresis. Since 1967 33 patients have been treated in this way. A group (6 patients) only received cyclophosphamide in a attack therapy of 15...25 mg/5g per body weight; a second group of 14 patients received the same dosis in combination with a double plasmapheresis. The third group of 13 patients in an advanced stage of the illness was treated polychemotherapeutically according to various schemes (COP-cyclophosphamide, vincristine, prednisone; COPP with Natulan) likewise in combination with double plasmapheresis. The observations made for 4 years in the two groups first mentioned showed favourable results in the second group with an average survival time of 35 months. In the third group only experiences of two years can be reported and thus a final answer cannot be given. However, it can already be stated that a clinical success requires the cytostatic therapy to be continued for a long time in combination with plasmapheresis.
D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007070:Immunoglobulin A / Q000378:metabolism; D007074:Immunoglobulin G / Q000378:metabolism; D007075:Immunoglobulin M / Q000378:metabolism; D010266:Paraproteins / Q000378:metabolism; D010954:Plasmacytoma / Q000188:drug therapy* / Q000628:therapy; D010956:Plasmapheresis; D011241:Prednisone / Q000627:therapeutic use; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010266:Paraproteins; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone
Klinische Erfahrungen mit der Langzeittherapie beim generalisierten Plasmozytom.